All In Biotech

Drug Trial Radar · NCT06423703

A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Primary Unilateral Bunionectomy

Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Jul 18, 2024

Primary completion

Jan 31, 2025

Study completion Jan 31, 2025

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.

Conditions

  • Acute Pain

Interventions

  • CebranopadolDrug

    once daily for 3 days

  • Oxycodone IRDrug

    four times per day for 3 days

  • Placebo OnlyDrug

    four times per day for 3 days

  • PlaceboDrug

    three times per day for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain NRS area under the curve: cebranopadol vs. placeboTime frame: 2-48 hours

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • ALLEVIATE 2 Site 001108

    Sheffield, Alabama

  • ALLEVIATE 2 Site 001106

    Little Rock, Arkansas

  • ALLEVIATE 2 Site 001103

    Tampa, Florida

  • ALLEVIATE 2 Site 001102

    Atlanta, Georgia

  • ALLEVIATE 2 Site 001107

    Overland Park, Kansas

  • ALLEVIATE 2 Site 001105

    Pasadena, Maryland

  • Alleviate 2 001113

    Houston, Texas

  • ALLEVIATE 2 Site 001104

    McAllen, Texas

  • ALLEVIATE 2 Site 001111

    San Antonio, Texas

  • ALLEVIATE 2 Site 001101

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.